135 related articles for article (PubMed ID: 16729907)
1. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
David KA; Milowsky MI; Kostakoglu L; Vallabhajosula S; Goldsmith SJ; Nanus DM; Bander NH
Clin Genitourin Cancer; 2006 Mar; 4(4):249-56. PubMed ID: 16729907
[TBL] [Abstract][Full Text] [Related]
2. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
Bander NH; Nanus DM; Milowsky MI; Kostakoglu L; Vallabahajosula S; Goldsmith SJ
Semin Oncol; 2003 Oct; 30(5):667-76. PubMed ID: 14571414
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
Vallabhajosula S; Goldsmith SJ; Kostakoglu L; Milowsky MI; Nanus DM; Bander NH
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7195s-7200s. PubMed ID: 16203821
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ; Bander NH
J Clin Oncol; 2004 Jul; 22(13):2522-31. PubMed ID: 15173215
[TBL] [Abstract][Full Text] [Related]
5. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
[TBL] [Abstract][Full Text] [Related]
6. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.
Tagawa ST; Beltran H; Vallabhajosula S; Goldsmith SJ; Osborne J; Matulich D; Petrillo K; Parmar S; Nanus DM; Bander NH
Cancer; 2010 Feb; 116(4 Suppl):1075-83. PubMed ID: 20127956
[TBL] [Abstract][Full Text] [Related]
7. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
Bander NH; Trabulsi EJ; Kostakoglu L; Yao D; Vallabhajosula S; Smith-Jones P; Joyce MA; Milowsky M; Nanus DM; Goldsmith SJ
J Urol; 2003 Nov; 170(5):1717-21. PubMed ID: 14532761
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
Bander NH; Milowsky MI; Nanus DM; Kostakoglu L; Vallabhajosula S; Goldsmith SJ
J Clin Oncol; 2005 Jul; 23(21):4591-601. PubMed ID: 15837970
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.
Slovin SF; Scher HI; Divgi CR; Reuter V; Sgouros G; Moore M; Weingard K; Pettengall R; Imbriaco M; El-Shirbiny A; Finn R; Bronstein J; Brett C; Milenic D; Dnistrian A; Shapiro L; Schlom J; Larson SM
Clin Cancer Res; 1998 Mar; 4(3):643-51. PubMed ID: 9533532
[TBL] [Abstract][Full Text] [Related]
11. What's in a Label? Radioimmunotherapy for metastatic prostate cancer.
Simone CB; Hahn SM
Clin Cancer Res; 2013 Sep; 19(18):4908-10. PubMed ID: 23926229
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
DeNardo SJ; Richman CM; Albrecht H; Burke PA; Natarajan A; Yuan A; Gregg JP; O'Donnell RT; DeNardo GL
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7187s-7194s. PubMed ID: 16203820
[TBL] [Abstract][Full Text] [Related]
13. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of prostate cancer.
Smith-Jones PM
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):297-304. PubMed ID: 15640793
[TBL] [Abstract][Full Text] [Related]
15. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
Vallabhajosula S; Goldsmith SJ; Hamacher KA; Kostakoglu L; Konishi S; Milowski MI; Nanus DM; Bander NH
J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
[TBL] [Abstract][Full Text] [Related]
16. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
[TBL] [Abstract][Full Text] [Related]
17. Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer.
Niaz MO; Sun M; Ramirez-Fort MK; Niaz MJ
Cureus; 2020 Feb; 12(2):e7107. PubMed ID: 32257655
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
Nanus DM; Milowsky MI; Kostakoglu L; Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Bander NH
J Urol; 2003 Dec; 170(6 Pt 2):S84-8; discussion S88-9. PubMed ID: 14610416
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
Kahn D; Austin JC; Maguire RT; Miller SJ; Gerstbrein J; Williams RD
Cancer Biother Radiopharm; 1999 Apr; 14(2):99-111. PubMed ID: 10850293
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.
O'Donnell RT; DeNardo SJ; Yuan A; Shen S; Richman CM; Lara PN; Griffith IJ; Goldstein DS; Kukis DL; Martinez GS; Mirick GR; DeNardo GL; Meyers FJ
Clin Cancer Res; 2001 Jun; 7(6):1561-8. PubMed ID: 11410491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]